A phase 3 trial shows serplulimab plus chemotherapy improved overall survival and 4-year survival rates vs chemotherapy alone in extensive-stage small cell #LungCancer, with durable benefit and manageable safety. https://t.co/iGTsqYyovq
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events.
https://t.co/52i1Sbr1sw
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. https://t.co/0doQhIrwi5
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. https://t.co/JehoSISuhO
This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #LungCancer and which patients might be considered for this treatment. https://t.co/8DAUoBMfLh
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events. https://t.co/vb1u8yOOhz
From @JAMA_current: In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in #tumors with high PD-L1 expression.
#ASCO26@ASCO
https://t.co/3f8lLL1jJv
🌟Fovinaciclib for First‑Line Therapy for Advanced Breast Cancer: A Randomized Clinical Trial, presented today at #ASCO26
📖 Free to read online from @JAMAOnc
https://t.co/Ro5fwncY50
A phase 3 trial demonstrated that fovinaciclib plus aromatase inhibitor showed significant and clinically improved progression-free survival with manageable safety in hormone receptor–positive, ERBB2-negative advanced #BreastCancer.
#ASCO26@ASCO
https://t.co/2XT5EUvh4g
A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior. What is your diagnosis? See the answer: https://t.co/54wuzkRnm1
✨Impact of Population‑Based Pathogenic Variant Testing on Risk‑Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study, presented today at #ASCO26
📖 Free to read online from @JAMAOnc
https://t.co/NKegGBSo3R
Among women with breast cancer gene pathogenic variants (PV), most would not have received high-risk screening based on clinical or polygenic risk, supporting the need for germline PV testing in risk-based #BreastCancer screening.
#ASCO26@ASCO
https://t.co/LE9jrMP5Z0
Older adults with advanced cancer mainly prioritized quality of life, but their treatment preferences were not associated with differences in survival, hospitalization, or adverse effects. https://t.co/n1c9pvbkpV
Study of veterans with cancer identified high rates of suicidal self-directed violence, with greatest risk in younger, female, American Indian or Alaska Native, and those with central nervous system, pancreas, liver, thyroid, or head and neck cancer.
https://t.co/1CHwZQ2vyi
This Review examines the clinical utility of circulating tumor DNA assays for detecting minimal residual disease in patients with early-stage breast cancer.
https://t.co/aNP1IUY4sR
✨Attending #ASCO26?
🌟 Explore our attendee page for the latest articles
🎧 Listen to podcasts
📚 Get For Authors resources from @JAMA_current, @JAMAOnc, and @JAMANetworkOpen
https://t.co/y1XoTqlFcw
PRIME is a validated, interpretable #PancreaticCancer risk model using routine clinical data, supporting risk-based case-finding and integration with biomarker testing for early detection. https://t.co/rqtjCmb3wE
In 2025, JAMA Oncology received 3738 manuscripts from 74 countries, with original scientific content impacting patient care, research, and policy.
Read the full Year in Review by JAMA Oncology Editor in Chief Mary L. (Nora) Disis, MD. https://t.co/NVjlLddVrZ
Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #BreastCancer after endocrine progression. https://t.co/pQs6FeBqNm